Docusign Envelope ID: 73CA4A5F-72DC-48C5-B6AE-EF119F0726A7

Pfizer ApS
Lautrupvang 8
DK-2750 Ballerup
Tlf.: 44 20 11 00
Fax: 44 20 11 01
www.pfizer.dk
DK66351912

Sjældne Diagnoser
Blekinge Boulevard 2, Høje Taastrup, Taastrup, 2630 Hovedstaden, Denmark
Att.: Lene Jensen

Ballerup, October 08, 2025

In Process

Agreement on support to:

Pfizer wishes to provide support to meeting and has therefore entered into this Agreement with Sjældne Diagnoser (hereafter referred to as the Recipient).

The purpose of this agreement shall be to support Sjældne Diagnoser to organise 40th anniversary meeting.

The agreement shall be in effect from November 07, 2025 to November 07, 2025.

Pfizer's financial commitment in relation to this Agreement shall be DKK 5.230,00 excl. VAT.

The amount is equivalent to the requested EUR 700.

Pfizer will not provide any non-financial support.

Disclaimer

The Recipient will ensure that the support is used solely for professional and scientific purposes in relation to the activity and undertakes that any surplus from the support not used in accordance herewith will be refunded.

Upon request from Pfizer the Recipient must document that the support is spend in accordance with the above-mentioned.

Furthermore the Recipient will be responsible for compliance with all applicable law.

Pfizer shall not be liable for damages of any kind and Pfizer provides no indemnification of any type.
By accepting this support from Pfizer, you agree that:

Docusign Envelope ID: 73CA4A5F-72DC-48C5-B6AE-EF119F0726A7

- The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper businessadvantage;

- Neither your entity nor, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly orindirectly offer or pay any money or anything of value in an effort to influence anyGovernment official or any other person in order for Pfizer to improperly obtain or retain business or gain any improper business advantage, and, have not accepted, and willnot accept in the future, such a payment;

- If the support is an educational grant or otherwise to support an educational program,your entity agrees to disclose the fact that Pfizer is providing financial support for the educational program

- This agreement will be publicly available on Pfizer's website (www.pfizer.dk) throughout the term of the agreement and 6 months thereafter. The information must also be made available on the Patient Association's website no later than 1 month after the PatientAssociation has received the financial benefit. The information must be available on the website for at least 2 years; and

- Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support has used or intends to use any portion of the support to improperly seek to influence any Government Official or any other person to obtain or retain business or gain a business advantage.

In Progress

Documentation

Upon Pfizer’s request, the Recipient shall provide documentation that the support is spend in accordance with the Agreement and that the combined support does not exceed the actual expenses. Any surplus shall be refunded to Pfizer.

Data Privacy

By signing this Agreement the Recipient agrees that Pfizer archives information about the Recipient and persons employed with the Recipient, who are or have been involved in this agreement. The Recipient carries the responsibility, that the persons who are involved in the agreement are informed and accept the processing and transfer of personal data., including name, contact details, and CVR-no in a global electronic system for processing of personal data. The electronic data processing system is accessible for a number of companies within the Pfizer group. The personal data can be transferred by Pfizer to other companies within the Pfizer group, to business partners as well as relevant governmental authorities, when this is necessary. Such recipients can be situated in countries outside the EC, e.g. the United States (so-called third-countries). For transfers from the EEA to countries not considered adequate by the European Commission, we have put in place adequate measures, such as by ensuring that the receiver is bound by EU Standard Contractual Clauses, to protect your personal data. By signing this Agreement the Recipient agrees that Pfizer may transfer such personal data to third countries in order to fulfil this Agreement and for the purpose of precise identification of Pfizer's business partners.

Docusign Envelope ID: 73CA4A5F-72DC-48C5-B6AE-EF119F0726A7

The Recipient is entitled to contact Pfizer, if the Recipient wishes to access the processed personal information about the Recipient. The Recipient is further entitled to have the relevant information changed or deleted. This applies for all persons mentioned in this section.

By signing this Agreement the Recipient confirms to have read and understood Pfizer's Representations and Warranties pursuant to Appendix A ("Representations and Warranties") and that the support is spend in accordance with the above mentioned terms and conditions.

We kindly ask you to return the signed agreement to Pfizer.

Signature of authorized signatory on behalf of Pfizer:

Dimitrios Maliokas

Date: 10/10/2025

Name: Dimitrios Maliokas

Title: EMEA MEET Operations Manager

In Process

Signature of authorized signatory on behalf of Sjældne Diagnoser:

Lene Jensen

Date: 21/10/2025

Name: Lene Jensen

Title: Direktør

Docusign Envelope ID: 73CA4A5F-72DC-48C5-B6AE-EF119F0726A7

Appendix A - Representations and Warranties

1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;

1.2 Neither your entity nor, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment;

1.3 If the support is an educational grant or otherwise to support an educational program, your entity agrees to disclose the fact that Pfizer is providing financial support for the educational program;

1.4 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support; and

1.5 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support has used or intends to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.